Isomorphic Labs Raises $5 Billion In Series C Funding Round Co-Led By Greenoaks And Sequoia Capital
Isomorphic Labs, a London-based AI drug discovery company founded and led by CEO Sir Demis Hassabis, raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital , with participation from Andr…
Isomorphic Labs, a London-based AI drug discovery company founded and led by CEO Sir Demis Hassabis, raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz (a16z), Alphabet and existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company will use the funding to advance its AI-powered drug design engine, scale its therapeutic candidate pipeline, expand its foundational simulation models and build global infrastructure for AI-led bioengineering as it moves its first drug candidates toward clinical trials.
FOUNDER: Sir Demis Hassabi
INVESTORS: Greenoaks, Sequoia Capital, Andreessen Horowitz (a16z), Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek, UK Sovereign AI Fund
ROUND: Series C AMOUNT: $5,000,000,000
HQ: London, United Kingdom
#VentureCapital #IsomorphicLabs #SirDemisHassabi #TradedVC
ABOUT THE DEAL
- Raise
- $5B
- Round
- Series C
- Company
- Isomorphic Labs
- Desk
- Deals
- Filed
- Nov 17, 2026
- Founders
- Sir Demis Hassabi
- Investors
- Greenoaks
- Sequoia Capital
- Andreessen Horowitz (a16z)
- Alphabet
- Thrive Capital
- MGX
- GV
- CapitalG
- Temasek
- UK Sovereign AI Fund